According to data presented at BIO and reported in the Patent Docs blog, 25% of the publicly traded biotechs ceased since the 4th Qtr of 2007. Fifty-two (52) company's discontinued operations and sixty-two (62) were acquired. There were only 14 IPOs. The net effect was a drop in the industry count from 394 public companies to only 294. According to a Bloomberg report, biotech acquisitions rose from 40 in 2007 to 55 in 2008, dropped to 38 in 2009, and stand at 21 this year.
Posted by Bruce Lehr October 12th 2010.